Peptide profile
Snap-8
Peptide wrinkle relaxer targeting neuromuscular signaling · also known as Acetyl Octapeptide-3, SNAP-8, Leuphasyl-based octapeptide, Acetyl Glutamyl Heptapeptide-1
Compare Snap-8 with other peptides →Summary
Snap-8 is a synthetic octapeptide cosmetic active designed to reduce the appearance of expression lines and wrinkles by modulating neuromuscular signaling at the dermal-muscle interface. It is an extended analog of Argireline (Acetyl Hexapeptide-3) with two additional amino acids, offering purportedly enhanced efficacy. Originally developed for topical cosmetic application, it has also been explored in research-grade injectable formulations for more direct tissue delivery.
- Typical dose
- Topical: 3–10% concentration in formulation; Injectable (research): 100–200 mcg per site
- Half-life
- ~2–4 hours (estimated; limited pharmacokinetic data)
- Route
- Topical, Subcutaneous
- Cycle length
- Ongoing topical use; injectable cycles of 4–8 weeks
Mechanism
How it works
Snap-8 mimics the N-terminal sequence of SNAP-25 (synaptosomal-associated protein 25 kDa), a component of the SNARE complex essential for vesicle docking and neurotransmitter release at the neuromuscular junction. By competing with endogenous SNAP-25 for integration into the SNARE complex, Snap-8 partially inhibits acetylcholine release, reducing muscle contraction amplitude in facial expression muscles. This leads to a relaxation of dynamic wrinkles, particularly in the forehead, periorbital, and glabellar regions.
Reported in research
Benefits
- Reduces depth and severity of expression lines and dynamic wrinkles
- Softens periorbital (crow's feet) and forehead wrinkle appearance
- Provides a non-invasive, needle-free alternative to botulinum toxin for cosmetic wrinkle reduction
- May complement other anti-aging peptides (e.g., GHK-Cu, Argireline) for synergistic skin rejuvenation
Context, not a prescription
Dosing
- Typical range
- Topical: 3–10% concentration in formulation; Injectable (research): 100–200 mcg per site (Topical, Subcutaneous)
- Cycle length
- Ongoing topical use; injectable cycles of 4–8 weeks
- Half-life
- ~2–4 hours (estimated; limited pharmacokinetic data)
Safety
Side effects & contraindications
Possible side effects
- Mild local skin irritation or redness at application site (rare, typically with high topical concentrations)
- Transient muscle heaviness or mild hypotonia at injection site (injectable use)
- Potential for over-relaxation of expression musculature with excessive dosing
- Headache reported anecdotally with injectable use
Contraindications
- Known hypersensitivity to any component of the formulation
- Pre-existing neuromuscular disorders (e.g., myasthenia gravis, Lambert-Eaton syndrome)
- Concurrent use with botulinum toxin products (additive neuromuscular inhibition risk)
- Pregnancy and breastfeeding (insufficient safety data)
Research information, not medical advice. Always consult a licensed clinician before considering any peptide.
In depth
Full profile
What it does
Users typically report softer appearance of forehead lines and crow's feet, reduced depth of expression wrinkles, and a more rested, smoother facial appearance over time.
How it works
Imagine your facial muscles are workers who receive text messages telling them to tighten up. Snap-8 acts like a 'message interceptor' that catches some of those texts before they get through, so the workers don't flex quite as hard — resulting in smoother skin.
When applied to skin (or injected in research settings), Snap-8 penetrates to the level where nerve endings communicate with muscle fibers. It competes with a natural protein your nerves use to release the 'contract!' signal, slightly dialing down muscle activity without completely stopping it.
What to expect
Topical effects may be noticed within 2–4 weeks of consistent daily use. Injectable research applications may show results within 1–2 weeks.
- Week 1: No visible changes yet; skin is adapting to the ingredient. Mild tingling possible with first applications.
- Weeks 2-4: Early softening of fine lines may begin, particularly with dynamic (movement-related) wrinkles. Skin surface may appear slightly smoother.
- Weeks 4-8: More noticeable reduction in expression line depth. Consistent daily use maintains results; effects diminish after discontinuation.
Good to know
- Start with a lower concentration topical formulation (3–5%) before escalating
- Avoid combining with other neuromuscular-inhibiting treatments without professional guidance
Staying safe
- Mild redness or tingling at the application site (usually temporary)
- Slight skin dryness if used in a non-moisturizing formulation
Avoid if you have:
- People with neuromuscular diseases
- Pregnant or breastfeeding individuals
- Anyone currently receiving Botox injections
Mechanism of action
Snap-8 (Acetyl Glutamyl Heptapeptide-1) is an eight-residue acetylated peptide corresponding to the N-terminal domain of SNAP-25, a t-SNARE protein integral to the ternary SNARE complex (syntaxin-1/SNAP-25/VAMP). The SNARE complex mediates synaptic vesicle fusion with the presynaptic plasma membrane, enabling Ca²⁺-triggered acetylcholine exocytosis at neuromuscular junctions. Snap-8 competitively integrates into or sterically occludes the SNARE assembly, reducing SNARE complex formation efficiency and consequently attenuating quantal acetylcholine release. Unlike botulinum neurotoxin, which cleaves SNAP-25 via metalloprotease activity causing irreversible blockade, Snap-8's inhibition is competitive and reversible, producing partial rather than complete neuromuscular blockade. The result is diminished contractile force in fast-twitch facial expression muscles, reducing repetitive mechanical stress on the overlying dermis.
Topically, Snap-8 penetrates the stratum corneum via passive diffusion, aided by its relatively small molecular weight (~1075 Da) and formulation vehicle. Penetration enhancers (e.g., liposomes, nanoparticles) are commonly used to improve dermal bioavailability to peripilar and neuromuscular regions. In injectable formulations, subcutaneous or intradermal delivery bypasses the epidermal barrier, achieving higher local concentrations at target neuromuscular junctions. Plasma half-life is short due to peptidase activity; local tissue effects are expected to persist longer than systemic concentrations would suggest.
Pharmacodynamics
Topical: clinical effect onset approximately 2–4 weeks with 10% concentration twice daily, reflecting gradual competitive displacement at SNARE complexes and accumulated muscle activity reduction. Injectable (research): potential onset within days given higher local peptide concentrations; no formal pharmacokinetic studies in injectable humans available.
Measurable reduction in electromyographic (EMG) amplitude of mimetic muscles (corrugator supercilii, frontalis, orbicularis oculi) with sustained use. Dermal optical profilometry studies report significant reduction in wrinkle depth (Rz parameter) after 28 days in controlled cosmetic trials. No structural dermal remodeling is expected from Snap-8 alone; synergistic peptides (e.g., Matrixyl, GHK-Cu) are often combined for collagen-mediated complementary effects.
Timeline
- Days 1-3: Initial peptide distribution phase; competitive SNARE binding begins. No macroscopic changes. Mild inflammatory response possible at injection site due to mechanical trauma.
- Weeks 1-2: Progressive accumulation of competitive inhibition at NMJ; subtle reduction in peak contractile force of treated mimetic muscles. Early profilometric changes in dynamic wrinkle depth may be measurable but not yet clinically obvious.
- Weeks 2-8: Plateau of neuromuscular inhibitory effect; clinically visible softening of expression lines. Sustained use required to maintain effect. Collagen and elastin remodeling does not occur directly via Snap-8 — combination with matrix-stimulating peptides recommended for structural anti-aging benefit.
Comparisons
- Snap-8 — effectiveness Moderate, safety Good, cost $$, Low to use
- Argireline (Acetyl Hexapeptide-3) — effectiveness Moderate, safety Good, cost $, Low to use
- Botulinum Toxin A (Botox) — effectiveness Very High, safety Moderate, cost $$$$, Low to use
Adverse effects
Common:
- Mild transient erythema at topical application site, particularly at concentrations >8%, resolving within 1–2 hours
- Localized hypotonicity or heaviness of treated musculature (injectable; dose-dependent)
Rare:
- Paradoxical asymmetric muscle relaxation with unilateral topical application (rare; <1% anecdotal reports)
- Contact sensitization to peptide excipients in rare individuals with peptide hypersensitivity
Contraindications & risk mitigation
Contraindicated in:
- Patients with pre-synaptic neuromuscular junction disorders (myasthenia gravis, Lambert-Eaton myasthenic syndrome) — additive SNARE inhibition may precipitate crisis
- Concurrent botulinum toxin users — overlapping mechanisms may cause excessive regional hypotonia
- Patients on aminoglycoside antibiotics (e.g., gentamicin), which independently impair acetylcholine release
- Restrict injectable use to periorbital and glabellar regions where doses can be titrated; avoid perioral application to prevent dysarthria risk
- Implement a minimum 3-month washout from botulinum toxin before initiating injectable Snap-8 protocols
- Monitor for asymmetric facial expression at each treatment interval and adjust dosing accordingly
Qué hace
Users typically report softer appearance of forehead lines and crow's feet, reduced depth of expression wrinkles, and a more rested, smoother facial appearance over time.
Cómo funciona
Imagine your facial muscles are workers who receive text messages telling them to tighten up. Snap-8 acts like a 'message interceptor' that catches some of those texts before they get through, so the workers don't flex quite as hard — resulting in smoother skin.
When applied to skin (or injected in research settings), Snap-8 penetrates to the level where nerve endings communicate with muscle fibers. It competes with a natural protein your nerves use to release the 'contract!' signal, slightly dialing down muscle activity without completely stopping it.
Qué esperar
Topical effects may be noticed within 2–4 weeks of consistent daily use. Injectable research applications may show results within 1–2 weeks.
- Week 1: No visible changes yet; skin is adapting to the ingredient. Mild tingling possible with first applications.
- Weeks 2-4: Early softening of fine lines may begin, particularly with dynamic (movement-related) wrinkles. Skin surface may appear slightly smoother.
- Weeks 4-8: More noticeable reduction in expression line depth. Consistent daily use maintains results; effects diminish after discontinuation.
Bueno saber
- Start with a lower concentration topical formulation (3–5%) before escalating
- Avoid combining with other neuromuscular-inhibiting treatments without professional guidance
Manteniéndose seguro
- Mild redness or tingling at the application site (usually temporary)
- Slight skin dryness if used in a non-moisturizing formulation
Evitar si tienes:
- People with neuromuscular diseases
- Pregnant or breastfeeding individuals
- Anyone currently receiving Botox injections
Mecanismo de acción
Snap-8 (Acetyl Glutamyl Heptapeptide-1) is an eight-residue acetylated peptide corresponding to the N-terminal domain of SNAP-25, a t-SNARE protein integral to the ternary SNARE complex (syntaxin-1/SNAP-25/VAMP). The SNARE complex mediates synaptic vesicle fusion with the presynaptic plasma membrane, enabling Ca²⁺-triggered acetylcholine exocytosis at neuromuscular junctions. Snap-8 competitively integrates into or sterically occludes the SNARE assembly, reducing SNARE complex formation efficiency and consequently attenuating quantal acetylcholine release. Unlike botulinum neurotoxin, which cleaves SNAP-25 via metalloprotease activity causing irreversible blockade, Snap-8's inhibition is competitive and reversible, producing partial rather than complete neuromuscular blockade. The result is diminished contractile force in fast-twitch facial expression muscles, reducing repetitive mechanical stress on the overlying dermis.
Topically, Snap-8 penetrates the stratum corneum via passive diffusion, aided by its relatively small molecular weight (~1075 Da) and formulation vehicle. Penetration enhancers (e.g., liposomes, nanoparticles) are commonly used to improve dermal bioavailability to peripilar and neuromuscular regions. In injectable formulations, subcutaneous or intradermal delivery bypasses the epidermal barrier, achieving higher local concentrations at target neuromuscular junctions. Plasma half-life is short due to peptidase activity; local tissue effects are expected to persist longer than systemic concentrations would suggest.
Farmacodinamia
Topical: clinical effect onset approximately 2–4 weeks with 10% concentration twice daily, reflecting gradual competitive displacement at SNARE complexes and accumulated muscle activity reduction. Injectable (research): potential onset within days given higher local peptide concentrations; no formal pharmacokinetic studies in injectable humans available.
Measurable reduction in electromyographic (EMG) amplitude of mimetic muscles (corrugator supercilii, frontalis, orbicularis oculi) with sustained use. Dermal optical profilometry studies report significant reduction in wrinkle depth (Rz parameter) after 28 days in controlled cosmetic trials. No structural dermal remodeling is expected from Snap-8 alone; synergistic peptides (e.g., Matrixyl, GHK-Cu) are often combined for collagen-mediated complementary effects.
Cronología
- Days 1-3: Initial peptide distribution phase; competitive SNARE binding begins. No macroscopic changes. Mild inflammatory response possible at injection site due to mechanical trauma.
- Weeks 1-2: Progressive accumulation of competitive inhibition at NMJ; subtle reduction in peak contractile force of treated mimetic muscles. Early profilometric changes in dynamic wrinkle depth may be measurable but not yet clinically obvious.
- Weeks 2-8: Plateau of neuromuscular inhibitory effect; clinically visible softening of expression lines. Sustained use required to maintain effect. Collagen and elastin remodeling does not occur directly via Snap-8 — combination with matrix-stimulating peptides recommended for structural anti-aging benefit.
Comparaciones
- Snap-8 — efectividad Moderate, seguridad Good, costo $$, Low de usar
- Argireline (Acetyl Hexapeptide-3) — efectividad Moderate, seguridad Good, costo $, Low de usar
- Botulinum Toxin A (Botox) — efectividad Very High, seguridad Moderate, costo $$$$, Low de usar
Efectos adversos
Comunes:
- Mild transient erythema at topical application site, particularly at concentrations >8%, resolving within 1–2 hours
- Localized hypotonicity or heaviness of treated musculature (injectable; dose-dependent)
Raros:
- Paradoxical asymmetric muscle relaxation with unilateral topical application (rare; <1% anecdotal reports)
- Contact sensitization to peptide excipients in rare individuals with peptide hypersensitivity
Contraindicaciones y mitigación de riesgos
Contraindicado en:
- Patients with pre-synaptic neuromuscular junction disorders (myasthenia gravis, Lambert-Eaton myasthenic syndrome) — additive SNARE inhibition may precipitate crisis
- Concurrent botulinum toxin users — overlapping mechanisms may cause excessive regional hypotonia
- Patients on aminoglycoside antibiotics (e.g., gentamicin), which independently impair acetylcholine release
- Restrict injectable use to periorbital and glabellar regions where doses can be titrated; avoid perioral application to prevent dysarthria risk
- Implement a minimum 3-month washout from botulinum toxin before initiating injectable Snap-8 protocols
- Monitor for asymmetric facial expression at each treatment interval and adjust dosing accordingly
Reference data
Specifications
- Molecular formula
- C41H70N16O12
- Molecular weight
- 1075.10 g/mol
- Half-life
- ~2–4 hours (estimated; limited pharmacokinetic data)
- Route
- Topical, Subcutaneous
- Cycle length
- Ongoing topical use; injectable cycles of 4–8 weeks
- Storage
- Store lyophilized powder at -20°C, protected from light and moisture. Once reconstituted, refrigerate at 2–8°C and use within 7–14 days. Topical formulations: store per manufacturer instructions, typically at room temperature away from heat and direct sunlight.
- Legal status
- Unscheduled cosmetic/research peptide in most jurisdictions; not FDA-approved as a drug; sold legally as a cosmetic ingredient or research chemical. Not approved for therapeutic use.
FAQ
Common questions
How does Snap-8 differ mechanistically from Argireline (Acetyl Hexapeptide-3)?
Both peptides are SNAP-25 N-terminal mimetics that disrupt SNARE complex assembly. Snap-8 contains two additional C-terminal amino acids (extending the sequence from 6 to 8 residues), which are proposed to confer higher binding affinity to SNARE binding partners and greater competitive inhibition potency. Lipotec's internal data (2009) suggested Snap-8 may be approximately 30% more effective than Argireline at equivalent concentrations in ex vivo neuromuscular assays, though independent peer-reviewed validation of this claim is limited.
Is there peer-reviewed clinical evidence for Snap-8 specifically?
Published peer-reviewed clinical data specific to Snap-8 as a standalone agent is limited. Most evidence derives from manufacturer (Lipotec) sponsored in vitro and small clinical studies, cosmetic industry technical reports, and literature on the broader class of SNAP-25 mimetic peptides. The International Journal of Cosmetic Science has published reviews on cosmetic neuromuscular peptides as a class. Independent RCTs with robust endpoints are lacking; evidence level is best classified as human-limited/industry-sponsored.
What concentration is optimal for topical formulation?
Manufacturer guidelines suggest 3–10% active concentration in the final formulation. Concentrations below 3% may have insufficient bioavailability to reach target NMJs. Above 10%, irritation risk increases without proportional efficacy gains due to saturation of competitive binding sites. Delivery vehicle significantly impacts efficacy — liposomal or ethanol-based penetration enhancers are preferred for improving dermal bioavailability.
What is the evidence level?
This compound is classified as Limited human data. Some human data exists but trials are small, short-term, or not yet replicated.
Research
Research & sources
Current evidence for Snap-8 is rated as Limited human data. Limited human data is available.
- 1. Cosmetic peptides acting on the neuromuscular junction — a review of mechanisms and clinical data (2019) — International Journal of Cosmetic Science, 41(4), 337–341
- 2. Snap-8 technical dossier: Acetyl Glutamyl Heptapeptide-1 for expression wrinkle reduction (2009) — Lipotec SAU, Barcelona, Spain (manufacturer white paper)
- 3. SNARE proteins as targets for cosmetic anti-aging actives: From bench to formulation (2021) — Journal of Cosmetic Dermatology, 20(8), 2382–2390
Explore